The gap between workers who say they want workplace support to quit vaping and the employers offering it is roughly 54 percentage points. That is not a communications problem. It is a program design problem, and it is concentrated at small and mid-size employers. If you lead HR or benefits at a company between 50 and 500 people, odds are your tobacco cessation program, if you have one, was built around cigarette smokers and has not been meaningfully updated for the vaping era.

The Prevalence Shift Most Benefits Plans Have Not Caught Up With

Adult e-cigarette use grew from 4.5% in 2019 to 6.5% in 2023, reaching 7.0% in 2024, according to CDC National Center for Health Statistics data. Cigarette smoking over the same period continued its decades-long decline, falling to 9.9% of adults in 2024. The two curves are converging faster than most employer benefits programs recognize.

The generational pattern is the part HR teams should pay attention to. Among adults aged 21 to 24, the 2023 vaping rate was 15.5%, meaning roughly one in six young working-age adults use e-cigarettes. Rates declined steadily with age. This is the first cohort entering the workforce for whom vaping, not smoking, is the dominant nicotine delivery method.

For employers, this has a specific implication. The tobacco cessation program you offered three years ago, built around cigarette smokers over 35, is serving a shrinking portion of your nicotine-using workforce. The cohort most likely to need cessation support now is exactly the cohort least likely to be using the product your program was designed for.

The Employer Coverage Gap

The numbers most frequently cited in vendor decks ("only 34% of employers offer a nicotine cessation program") are outdated. The current picture, based on peer-reviewed employer surveys, is both better and worse than that statistic suggests.

KFF's 2024 Employer Health Benefits Survey reports that 54% of small firms and 79% of large firms offer at least one program in smoking cessation, weight management, or behavioral coaching. The 2025 update raised those figures to 56% and 83%. Those headline numbers make coverage look reasonable, but they bundle three different benefit types into a single question, and none of them capture vaping-specific coverage at all.

The sharper, vaping-specific data point comes from Truth Initiative research published in the Journal of Occupational and Environmental Medicine. In a survey of 1,607 employees at companies with more than 150 workers, roughly one-third (31%) of workplaces offered a quit-vaping program, while 85% of employees said such a program was important to them. That is a 54-point employer-employee recognition gap.

A Health Affairs analysis identified a related gap at the small-employer end: 47% of small employers applying tobacco surcharges to their health plan premiums offered no tobacco cessation program to help employees quit. The penalty was applied. The support was not provided.

Why Vaping Cessation Is Not Just Smoking Cessation With a Different Product

The most common assumption in benefits design is that if your program handles cigarette smokers, it handles vapers. The peer-reviewed evidence says that assumption needs updating, though the picture is more nuanced than vendor marketing typically presents.

Four distinctions matter.

Dependence profiles differ. A 2019 study in the International Journal of Environmental Research and Public Health found nicotine dependence scores among exclusive e-cigarette users were more than twice as high as among traditional cigarette smokers in a young-adult sample. Among dual users, dependence was higher when using e-cigarettes than when using cigarettes.

Device chemistry changed the addiction curve. Modern pod-based devices using nicotine salts can carry concentrations up to 50 mg/mL. A single pod from a major manufacturer contains roughly the nicotine equivalent of 20 cigarettes, according to Johns Hopkins Medicine and Yale Medicine clinical summaries. The implication for cessation programming is that the baseline nicotine load employees are trying to step down from is often higher than traditional smoking cessation protocols were designed to handle.

Use patterns do not match. Cigarette smokers are constrained by cigarette length, smoke visibility, and the need to step outside. Vapers are not. Pod-based devices produce minimal visible vapor and can be used discreetly at a desk, in a bathroom, or in a meeting. Use is distributed across the day rather than clustered at breaks. This matters because many workplace cessation programs are built around the "smoke break" as the identifiable behavioral unit. That unit does not map to vaping.

Clinical guidelines have not caught up. A 2023 modified Delphi expert panel published in Addictive Behaviors Reports stated directly that "there are currently no evidence-based clinical guidelines available for e-cigarette or vaping cessation." Panelists reached consensus on 24 recommendations across eight domains, but the field is explicitly emerging rather than settled. This is worth flagging honestly: any vendor claiming a "proven vaping-specific protocol" is overstating what the evidence currently supports.

The Absenteeism Cost Most Cessation Business Cases Are Missing

A peer-reviewed 2025 analysis of 2022 National Survey on Drug Use and Health data, covering 30,591 employed adults, found past-month nicotine vaping was associated with a 34% higher incidence of missed work from illness or injury and a 65% higher incidence of skipped work days, after adjustment for demographics and other substance use.

These are associations rather than established causation, but the sample size and statistical controls make this the strongest data point currently connecting vaping to workplace productivity in the peer-reviewed literature.

For HR leaders tracking the cost of unhealthy habits in their workforce, this is the productivity signal that has been missing from most cessation business cases. The absenteeism impact is measurable, and it is concentrated in the same early-career demographic that is hardest to replace.

What the Evidence Supports for Employer Cessation Programs

The most rigorously studied vaping cessation intervention to date is Truth Initiative's "This is Quitting" text-message program. A randomized controlled trial published in JAMA Internal Medicine with 2,588 young adults aged 18 to 24 found participants in the text-message group were 35% more likely to quit at 7-month follow-up compared with controls (odds ratio 1.39, 95% CI 1.15 to 1.68, p less than 0.001). A 2024 JAMA publication extended effectiveness findings to teens.

A 2025 systematic review in the Journal of Medical Internet Research, examining digital interventions for vaping cessation specifically, found that programs incorporating personalized messaging, behavioral tracking, and social or interactive features showed greater engagement and retention. The reviewers noted that rigorous outcomes data are still accumulating, which is consistent with the Delphi panel's conclusion that the evidence base is emerging.

What does not work is what most employers default to: a single lunch-and-learn, a resource guide, or a vaping module bolted onto a cigarette-focused program. Educational interventions alone show diminishing effects over time, and programs that treat vaping as a minor variation of cigarette smoking tend to miss the use-pattern and dependence-profile differences the peer-reviewed research has documented.

Where This Leaves Small and Mid-Size Employers

The coverage gap is most acute at smaller companies. KFF's 2024 data show only 54% of small firms offer any program across the smoking cessation, weight management, or behavioral coaching categories, compared to 79% of large firms. Only 13% of employers of any size offer elder care referral services, which signals a broader pattern: smaller companies tend to lag on the newest benefit categories by three to five years, which is why vendor-agnostic guidance on wellness programs for small businesses is worth reviewing against your current coverage.

For a small or mid-size employer rethinking their tobacco benefit, the implication is not to swap cigarette cessation for vaping cessation. Both still have users in most workforces.

Programs built around an annual flu-shot-style cessation event are not structurally equipped for this.

How habits work is ultimately the question underneath a working cessation program, whether the product is a cigarette, a pod, or anything else. The behavioral science applies to nicotine, not to a specific delivery device.

A Different Question to Ask

The recognition gap between 85% of employees wanting quit-vaping support and 31% of employers offering it is not a failure of HR intent. HR leaders care about this. The gap exists because vaping emerged faster than benefits design cycles, the cessation programs most plans offer were architected for cigarettes, and the evidence base for vaping-specific cessation is still emerging in the peer-reviewed literature.

If your tobacco cessation program was last meaningfully updated before 2020, there is a reasonable chance it is serving a shrinking portion of your nicotine-using workforce and missing the employees most likely to need support. For benefits advisors reviewing cessation coverage across client plans, the same question worth asking applies at portfolio scale: how many of your employer clients are running cigarette-era programs against a vaping-era workforce?